CJC-1295: The Complete Guide to the GHRH Analog Peptide (2026)

CJC-1295 is one of the most widely used peptides in the growth hormone optimization space — and one of the most frequently misunderstood. The name refers to two chemically distinct compounds that behave very differently in the body, and the confusion between them is responsible for a significant portion of the unpredictable results people report. Getting this distinction right is the foundation of everything else in this guide.

At its core, CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) — the hypothalamic peptide that signals the pituitary gland to produce and release growth hormone (GH). Unlike exogenous recombinant human growth hormone (rhGH), which bypasses the pituitary entirely, CJC-1295 works through the body's own GH machinery. The pituitary responds, the feedback loops engage, and IGF-1 rises downstream. This is a meaningfully different physiological approach.

This guide covers the science, the evidence, dosing protocols (including the popular CJC-1295 + Ipamorelin stack), side effects, and the rapidly evolving regulatory landscape in 2026.

What Is CJC-1295?

CJC-1295 was developed in the early 2000s by ConjuChem Biotechnologies, a Montreal-based biotech company, as an improvement on earlier GHRH analogs like sermorelin. The core problem with native GHRH(1-29) — the biologically active fragment — is its extremely short plasma half-life: just a few minutes, due to rapid enzymatic degradation.

ConjuChem's solution was to make four amino acid substitutions at positions known to be vulnerable to cleavage by plasma peptidases, dramatically extending stability without meaningfully disrupting receptor binding. This stabilized base peptide is known as Modified GRF 1-29 (Mod GRF 1-29) — the version without DAC. The company then added a separate albumin-binding technology (the Drug Affinity Complex, or DAC) to create what became known as CJC-1295 with DAC.

The DAC vs. No-DAC Distinction: The Most Important Thing to Understand

The single most consequential distinction in CJC-1295 use is whether the compound includes the DAC (Drug Affinity Complex) modification or not. These are not equivalent products with slightly different half-lives — they produce fundamentally different physiological effects.

CJC-1295 With DAC

The DAC modification adds a maleimidopropionyl (MPA) group to a lysine residue at position 30. Within minutes of subcutaneous injection, this group forms a covalent, irreversible bond with cysteine-34 on serum albumin in the bloodstream. Because albumin itself has a ~20-day half-life, the peptide is effectively "piggybacking" on albumin, creating a slow-release depot.

The result: a plasma half-life of 5.8–8.1 days, confirmed in human pharmacokinetic studies. A single injection elevates GH and IGF-1 for up to 9–11 days; with weekly dosing, IGF-1 remains tonically elevated above baseline for 28+ days.

This sustained, continuous GH receptor stimulation departs significantly from the body's natural pulsatile GH secretion pattern. Some practitioners argue this tonic signaling reduces pituitary sensitivity over time and raises theoretical concerns around sustained IGF-1 elevation.

CJC-1295 Without DAC (Mod GRF 1-29)

Without the albumin-binding DAC component, Mod GRF 1-29 circulates freely, is degraded by plasma peptidases, and has a half-life of approximately 30 minutes, with full clearance within 2–3 hours. Each injection produces a brief, sharp GHRH pulse that triggers a discrete GH spike at the pituitary — closely mimicking the natural ultradian GH pulse pattern.

Most practitioners consider this pulsatile profile more physiologically appropriate, as it preserves the body's GH feedback regulation. The trade-off is more frequent injections.

Important naming note: Market labeling is inconsistent. Products sold as "Mod GRF 1-29," "Modified GRF 1-29," and "CJC-1295 no DAC" are chemically identical. The name "CJC-1295" originally referred only to the DAC version, but is now used loosely for both. Always verify DAC status before purchasing or prescribing.

Mechanism of Action

Both forms of CJC-1295 work through the same initial pathway: GHRH receptor (GHRHR) agonism on somatotroph cells in the anterior pituitary. The GHRHR is a Gs protein-coupled receptor; its activation raises intracellular cAMP, which drives both GH gene transcription and exocytosis of stored GH into systemic circulation.

Circulating GH then reaches the liver (and peripheral tissues), binds GH receptors, and triggers production of IGF-1 (Insulin-like Growth Factor 1) — the primary mediator of GH's downstream effects on muscle, fat, bone, and connective tissue.

Critically, CJC-1295 is a secretagogue, not a replacement. It prompts the pituitary to release more of its own stored GH. This preserves the negative feedback loop (GH and IGF-1 feed back to suppress GHRH signaling) — a key safety advantage over exogenous rhGH, which completely bypasses this regulation. With Mod GRF 1-29, the feedback loop engages normally after each pulse. With the DAC version's continuous signal, this feedback can be overridden.

Clinical Evidence

The evidence base for CJC-1295 is anchored in one well-designed human study. Every popular benefit claim about muscle gain, fat loss, or improved recovery extrapolates from known GH/IGF-1 biology and animal data — not completed human efficacy trials.

Teichman et al. (2006) — Journal of Clinical Endocrinology & Metabolism

This remains the definitive human pharmacokinetic reference. The randomized, double-blind, placebo-controlled dose-escalation study enrolled healthy adults aged 21–61, administering single subcutaneous injections at 30, 60, and 125 mcg/kg.

Key outcomes:

• Single injections produced 2- to 10-fold increases in mean plasma GH lasting 6+ days
• IGF-1 elevated 1.5- to 3-fold for 9–11 days post-injection
• After multiple weekly doses, IGF-1 remained above baseline for up to 28 days
• Half-life confirmed at 5.8–8.1 days
• "Safe and relatively well tolerated, particularly at doses of 30 or 60 mcg/kg"

A 2009 study by Walker et al. confirmed GH/IGF-1 axis activation and documented changes in IGF-binding proteins in normal adults. Preclinical data from mouse models has shown CJC-1295 + Ipamorelin combination improved maximal tetanic muscle tension in glucocorticoid-induced muscle loss models.

No completed human trial has measured body composition, injury recovery, or quality-of-life outcomes. This gap between the peptide's mechanistic plausibility and actual human efficacy data is important context for anyone considering its use.

Dosing Protocols

CJC-1295 With DAC

• Typical dose: 1–2 mg (1,000–2,000 mcg) per week
• Frequency: Once weekly subcutaneous injection; or split as 500–1,000 mcg twice weekly
• Injection site: Abdomen, flanks, or thigh (subcutaneous)
• Cycle: Typically 8–12 weeks on, 4 weeks off

CJC-1295 Without DAC (Mod GRF 1-29)

• Dose per injection: 100–300 mcg
• Beginner / wellness protocol: 100 mcg once daily, pre-sleep
• Intermediate: 100 mcg upon waking (fasted) + 100 mcg pre-sleep
• Advanced / performance: 100 mcg on waking + 100 mcg post-workout + 100 mcg pre-sleep
• Timing rule: Always administer on an empty stomach — food (especially carbohydrates and fat) blunts GH release significantly. Wait at least 2 hours after eating.
• Cycle: 5 days on / 2 days off to preserve receptor sensitivity; 8–12 weeks followed by a 4-week break

CJC-1295 + Ipamorelin Stack

This is the most widely used peptide combination in the GH optimization space, and for good reason: the two peptides work through independent receptor systems that converge on the same output.

• CJC-1295 (Mod GRF 1-29) activates the GHRH receptor pathway — telling the pituitary "release GH"
• Ipamorelin is a ghrelin mimetic (GHS-R agonist) that activates a separate GH-release pathway and simultaneously suppresses somatostatin (the GH-inhibiting hormone)

Together, they can produce 2–3x greater GH output than either peptide alone. Ipamorelin's notable advantage over older GHRPs (like GHRP-6 and GHRP-2) is its selectivity — it does not significantly raise cortisol, prolactin, or ACTH, making the combination cleaner.

Standard stack protocol:

• 100–300 mcg CJC-1295 no DAC + 100–300 mcg Ipamorelin per injection
• Both peptides can be mixed in the same syringe for a single subcutaneous injection
• Pre-sleep dosing is most common (aligns with the natural nocturnal GH surge during slow-wave sleep); pre-workout + pre-sleep for performance goals
• Cycle: 5 days on / 2 days off; 8–12 weeks on, 4 weeks off

Side Effects and Safety

Common Side Effects

• Water retention: The most frequently reported side effect; typically emerges in weeks 8–16. Manifests as transient weight gain (1–3 kg), facial puffiness, or swollen extremities. Usually resolves with dose reduction or cycling off.
• Injection site reactions: Redness, mild swelling, or irritation at the subcutaneous injection site
• Facial flushing / head rush: Reported shortly post-injection, particularly at higher doses; transient
• Headache: Mild, dose-related
• Fatigue: Occasional post-injection lethargy

Less Common but Significant

• Carpal tunnel syndrome: Documented in the Teichman clinical trial at 4.3% incidence (2 of 46 participants) at higher doses. Fluid accumulation in the carpal tunnel compresses the median nerve. Both cases resolved after dose reduction.
• Joint aches (arthralgia): Reflects fluid shifts in synovial tissue with GH elevation; more common at higher doses
• Insulin resistance / elevated fasting glucose: Sustained GH elevation has anti-insulin effects. This is a greater concern with the DAC version's tonic signaling than with pulsatile Mod GRF 1-29. Extended use warrants periodic fasting glucose monitoring.

The Cancer Question

Elevated IGF-1 is epidemiologically associated with increased relative risk of prostate, breast, and colorectal cancers in population studies. IGF-1 is a potent mitogen that promotes cell proliferation and inhibits apoptosis — theoretically able to accelerate growth of pre-existing, undetected malignancies.

The important distinction: decades of pharmacovigilance data from GH replacement therapy in GH-deficient adults, which produces similar IGF-1 elevations, has not demonstrated increased cancer incidence. The emerging consensus is that GH/IGF-1 does not initiate cancer but may promote growth of existing disease. CJC-1295 should not be used by anyone with a known or suspected active malignancy. Baseline IGF-1 testing before starting, and periodic monitoring during use, is standard practice in clinical settings.

Legal and Regulatory Status (2024–2026)

CJC-1295's regulatory status is one of the most dynamic in the peptide space right now.

CJC-1295 has never received FDA approval as a drug product. In 2023, the FDA placed it on the Category 2 interim 503A bulks list, effectively restricting licensed compounding pharmacies from preparing it. In September 2024, the FDA removed CJC-1295 from Category 2 (due to nominator withdrawal) — but this did not restore compounding access; it sent the peptide to formal PCAC review.

At the December 4, 2024 PCAC meeting, the FDA's own analysis recommended against including CJC-1295 on the 503A Bulks list, citing cardiac adverse event signals, immunogenicity concerns, and impurity issues.

Then came a significant shift. In February 2026, HHS Secretary Robert F. Kennedy Jr. publicly signaled that approximately 14 of the 19 restricted peptides — including CJC-1295 — are expected to return to Category 1 status, restoring the legal compounding pathway. The FDA has scheduled an outside advisory panel for July 23–24, 2026, with a final determination expected by late 2026 or early 2027.

As of April 2026: CJC-1295 is not legally compoundable by licensed 503A/503B pharmacies under current formal rules, though a restoration of access appears likely. It remains accessible through research chemical suppliers marketed as "for research only." Any legitimate clinical use requires physician oversight.

Storage and Reconstitution

CJC-1295 is sold as a lyophilized (freeze-dried) powder in sealed vials, typically 2 mg or 5 mg.

Pre-reconstitution storage:

• Long-term: −20°C (−4°F) freezer, away from light and moisture; stable for 24–36 months
• Short-term (vials in active use): refrigerator at 2–8°C
• Avoid repeated freeze-thaw cycles

Reconstitution protocol:

1. Allow vial to reach room temperature before opening
2. Use bacteriostatic water (BW) — the 0.9% benzyl alcohol preserves the reconstituted solution for up to 28 days. Sterile water for injection (WFI) can be used but reduces shelf life.
3. Inject BW slowly down the inner wall of the vial — never directly onto the lyophilized cake
4. Roll gently between fingers to dissolve; do not shake (mechanical agitation denatures the peptide)
5. Solution should be clear and colorless when complete

Example math: Adding 2 mL of bacteriostatic water to a 5 mg vial = 2,500 mcg/mL. A 100 mcg dose = 0.04 mL drawn into an insulin syringe.

Post-reconstitution: Refrigerate at 2–8°C; do not freeze; discard after 28 days. Even 4–6 hours at room temperature can reduce potency by 30–50% — draw and administer promptly.

Who Uses CJC-1295 and Why

Anti-aging adults (40–60+): GH declines approximately 15% per decade after age 30 (the "somatopause"). CJC-1295 is used to address declining muscle mass, increasing adiposity, lower energy, reduced bone density, and slower healing. Because it stimulates the pituitary's own GH rather than replacing it externally, it preserves the feedback regulation that rhGH bypasses.

Athletes and performance users: Lean mass preservation during cutting phases, accelerated recovery from training-induced muscle damage, fat loss (particularly visceral), and connective tissue repair.

Sleep-focused users: The largest natural GH pulse occurs during slow-wave sleep, approximately 60–90 minutes after sleep onset. Pre-bedtime injection amplifies this natural pulse. Many users report improved sleep depth within 1–2 weeks — consistent with the known sleep-promoting effects of GH, though human trial data on this specific outcome is lacking.

Post-injury recovery: Connective tissue repair, collagen synthesis, and wound healing are GH/IGF-1 dependent. CJC-1295 is used clinically in some settings for patients recovering from injuries or surgeries, or with conditions causing muscle wasting.

Conclusion

CJC-1295 occupies an interesting position in peptide medicine: the pharmacokinetics are well characterized (the 2006 Teichman study is robust), the mechanism is sound, and the biological plausibility of the claimed benefits is strong — but the gap between "plausible from mechanism" and "proven in humans" remains wide. No completed human RCT has measured the body composition or recovery outcomes people are most interested in.

The DAC vs. no-DAC distinction matters enormously in practice. Most clinicians who work with this peptide professionally prefer Mod GRF 1-29 (no DAC) because it preserves pulsatile GH physiology and natural feedback regulation. The CJC-1295 + Ipamorelin combination represents the current clinical standard for GH peptide optimization, offering mechanistic synergy through independent receptor pathways.

The regulatory picture is actively shifting. The expected restoration of compounding access in late 2026 may substantially change how CJC-1295 is prescribed and accessed. Anyone interested in using it should work with a physician who can order baseline IGF-1 testing, monitor for side effects, and navigate the evolving legal landscape.

This article is for educational and informational purposes only. CJC-1295 is not FDA-approved and requires physician oversight in any legitimate clinical context. Consult a qualified healthcare provider before starting any peptide therapy.